These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 29755341)

  • 1. Plasma Biomarkers Differentiate Parkinson's Disease From Atypical Parkinsonism Syndromes.
    Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ
    Front Aging Neurosci; 2018; 10():123. PubMed ID: 29755341
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
    Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
    Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
    Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligomeric α-synuclein and tau aggregates in NDEVs differentiate Parkinson's disease from atypical parkinsonisms.
    Meloni M; Agliardi C; Guerini FR; Zanzottera M; Bolognesi E; Picciolini S; Marano M; Magliozzi A; Di Fonzo A; Arighi A; Fenoglio C; Franco G; Arienti F; Saibene FL; Navarro J; Clerici M
    Neurobiol Dis; 2023 Jan; 176():105947. PubMed ID: 36481435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson's disease complicated by psychosis or dementia in a Sardinian population.
    Cannas A; Solla P; Borghero G; Floris GL; Chio A; Mascia MM; Modugno N; Muroni A; Orofino G; Di Stefano F; Calvo A; Moglia C; Restagno G; Meloni M; Farris R; Ciaccio D; Puddu R; Vacca MI; Melis R; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Marrosu MG; Marrosu F
    J Neurol; 2015 Nov; 262(11):2498-503. PubMed ID: 26275564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Assessment of 10 Biomarker Candidates Focusing on α-Synuclein-Related Disorders.
    Schulz I; Kruse N; Gera RG; Kremer T; Cedarbaum J; Barbour R; Zago W; Schade S; Otte B; Bartl M; Hutten SJ; Trenkwalder C; Mollenhauer B
    Mov Disord; 2021 Dec; 36(12):2874-2887. PubMed ID: 34363416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal Fluid
    Constantinides VC; Majbour NK; Paraskevas GP; Abdi I; Safieh-Garabedian B; Stefanis L; El-Agnaf OM; Kapaki E
    Brain Sci; 2021 Jan; 11(1):. PubMed ID: 33477387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Differential Diagnosis and Treatment of Atypical Parkinsonism.
    Levin J; Kurz A; Arzberger T; Giese A; Höglinger GU
    Dtsch Arztebl Int; 2016 Feb; 113(5):61-9. PubMed ID: 26900156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
    Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
    J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Oligomeric α-Synuclein and p-tau181 in Progressive Supranuclear Palsy and Parkinson's Disease.
    Cristiani CM; Scaramuzzino L; Quattrone A; Parrotta EI; Cuda G; Quattrone A
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma α-synuclein and phosphorylated tau 181 as a diagnostic biomarker panel for de novo Parkinson's disease.
    Ren J; Pan C; Wang Y; Xue C; Lin H; Xu J; Wang H; Zhang W; Xu P; Chen Y; Liu W
    J Neurochem; 2022 Jun; 161(6):506-515. PubMed ID: 35234288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias.
    Stamelou M; Diehl-Schmid J; Hapfelmeier A; Kontaxopoulou D; Stefanis L; Oertel WH; Bhatia KP; Papageorgiou SG; Höglinger GU
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1264-8. PubMed ID: 26324212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classifications of Neurodegenerative Disorders Using a Multiplex Blood Biomarkers-Based Machine Learning Model.
    Lin CH; Chiu SI; Chen TF; Jang JR; Chiu MJ
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32967146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum neuronal exosomes predict and differentiate Parkinson's disease from atypical parkinsonism.
    Jiang C; Hopfner F; Katsikoudi A; Hein R; Catli C; Evetts S; Huang Y; Wang H; Ryder JW; Kuhlenbaeumer G; Deuschl G; Padovani A; Berg D; Borroni B; Hu MT; Davis JJ; Tofaris GK
    J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):720-729. PubMed ID: 32273329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dystonia between Parkinson's disease and atypical parkinsonism: The clinical usefulness of dystonia distribution and characteristics in the differential diagnosis of parkinsonism.
    Yoon WT
    Neurol Neurochir Pol; 2018; 52(1):48-53. PubMed ID: 29196058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.